预约演示
更新于：2026-06-30
Clobazam
氯巴占
更新于：2026-06-30
概要
基本信息
药物类型 小分子化药 |
别名 1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine、7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione、CLB + [18] |
作用方式 激动剂 |
作用机制 GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H13ClN2O2 |
InChIKeyCXOXHMZGEKVPMT-UHFFFAOYSA-N |
CAS号22316-47-8 |
关联
41
项与 氯巴占 相关的临床试验CTR20254346
氯巴占口服混悬液人体生物等效性试验（预试验）
IRCT20220211053992N49
In vivo fasted-state bioequivalence study of Clobazam 250 mg/ml suspension manufactured by Ashbal shimi Pharmaceutical Co. compared to innovator product
CTR20243975
Frisium和依诺思治疗Lennox-Gastaut综合征的多中心、随机、交叉、对照临床试验
100 项与 氯巴占 相关的临床结果
登录后查看更多信息
100 项与 氯巴占 相关的转化医学
登录后查看更多信息
100 项与 氯巴占 相关的专利（医药）
登录后查看更多信息
2,445
项与 氯巴占 相关的文献（医药）2026-08-01EPILEPSY & BEHAVIOR
Impact of antiseizure medications on thyroid function in persons with epilepsy
Article
作者: Menon, Ramshekhar N ; Bhasi, Ankith ; Radhakrishnan, Ashalatha ; Koshy, Kiren G ; Rohith, Maraludevanapura Govindaiah ; Ram, Nadarajan Aravind ; Manisha, K Y ; Bharanidharan, Gurumurthy
BACKGROUND:
Antiseizure medications (ASMs) are central to epilepsy management but may disrupt endocrine function, particularly thyroid homeostasis. Subclinical and central hypothyroidism are increasingly recognized among ASM users, yet routine thyroid monitoring remains uncommon.
OBJECTIVE:
To evaluate the prevalence and patterns of thyroid dysfunction in epilepsy patients on ASMs and compare the impact of older versus newer ASMs on thyroid function.
METHODS:
This cross-sectional study included 203 patients with epilepsy admitted to a tertiary epilepsy care centre in South India between July 2013 and March 2014. Patients with known thyroid disorders or other conditions affecting thyroid function were excluded. Thyroid function tests (TSH, fT3, fT4) were performed. Subclinical hypothyroidism was defined as elevated TSH with normal fT3/fT4; central hypothyroidism as low fT3/fT4 with normal or low TSH. ASMs were categorized into older and newer groups. Data were analysed using SPSS with appropriate parametric and non-parametric methods.
RESULTS:
Subclinical hypothyroidism was found in 11.3% of patients, more common in generalized epilepsy (56.5%) than focal epilepsy (43.5%) (p = 0.005). Valproate and clonazepam were most frequently associated. Among patients on monotherapy, none on newer ASMs had subclinical hypothyroidism, whereas 14.9% on older ASMs were affected (p = 0.35). Central hypothyroidism occurred in 10.3%, predominantly among users of zonisamide, phenobarbital, oxcarbazepine, and clobazam. Both older and newer ASM groups showed similar central hypothyroidism rates (9.6% versus 9.1%) CONCLUSION: Both older and newer ASMs exert clinically significant effects on thyroid homeostasis. Older ASMs were more often linked to subclinical hypothyroidism, while central hypothyroidism risk was comparable across ASM types. Annual thyroid screening is recommended to detect dysfunction early and prevent metabolic and cardiovascular complications.
2026-08-01EPILEPSY & BEHAVIOR
Caregiver perspectives on disease burden and treatment priorities in KCNT1-related disorders
Article
作者: Abuhl, Amanda ; Poliquin, Sarah ; Bearden, David ; Drislane, Sarah ; Esposito, Kaitlyn ; Wright, Megan ; Bryan, Brad A ; Faria, Victor ; Boyce, Danielle ; Rosenberg, Allison ; West, Justin ; Terry, Ian
BACKGROUND:
Pathogenic variants in KCNT1, encoding the sodium-activated potassium channel KNa1.1 (Slack), cause severe developmental and epileptic encephalopathies marked by early-onset, treatment-resistant seizures and profound neurodevelopmental impairment. While clinical and electrophysiological features are well described, systematic caregiver-reported data on treatment effectiveness and family impact are limited.
METHODS:
The KCNT1 Epilepsy Foundation established an international online caregiver-reported registry. Caregivers of individuals with a clinical and/or genetic diagnosis of a KCNT1-related disorder completed structured surveys between April 2023 and January 2024. Data included demographics, genetic variants, seizure characteristics, treatment history, sleep behaviors, quality of life, and family impact using validated and custom instruments.
RESULTS:
Data from 62 individuals across 13 countries were analyzed. Seizure onset was early (median: 1 month), with diagnosis occurring shortly thereafter (median: 4 months). Sixteen distinct KCNT1 missense variants were reported across the cohort. Caregivers reported a high treatment burden, with a median of 2.5 concurrent antiseizure therapies. The ketogenic diet, clobazam, phenobarbital, and levetiracetam, and vagus nerve stimulation were perceived as highly beneficial, while many conventional antiseizure medications showed limited benefit or worsening. Profound challenges were reported, particularly in cognitive and physical functioning, along with substantial emotional and practical family burden. Treatment priorities extended beyond seizure control to include communication, overall health, and quality of life, with notable gaps between priorities and perceived effectiveness.
CONCLUSIONS:
Caregiver-reported data demonstrate severe burden and substantial unmet needs in KCNT1-related disorders, highlighting the importance of patient- and family-centered outcome measures in care and therapeutic development.
2026-07-01MARINE ENVIRONMENTAL RESEARCH
Occurrence, seasonal variability, and ecological risk of emerging contaminants in estuarine and nearshore waters around Hainan Island, China
Article
作者: Sun, Chuhan ; Niu, Haochen ; Zhao, Hongwei ; Zhou, Xueqing ; Huang, Yuehua ; Li, Sichen
Emerging contaminants (ECs), particularly pharmaceuticals and personal care products (PPCPs), have been increasingly detected in aquatic environments, raising global concerns due to their potential adverse effects on ecological health. As the ultimate sink for land-based pollutants, the nearshore waters around Hainan Island are particularly vulnerable to PPCPs contamination. The rapid development of the Hainan Free Trade Port has intensified environmental pressures on Hainan Island; however, data regarding PPCPs contamination in its zones remain limited. To address this knowledge gap, this study investigated the occurrence, seasonal variation, and ecological risks of five antifungal agents-climbazole (CLB), fluconazole (FLZ), clotrimazole (CTZ), miconazole (MCZ), and ketoconazole (KTZ)-as well as the insect repellent N,N-diethyl-m-toluamide (DEET) in estuarine and nearshore environments influenced by 12 major rivers around Hainan Island, China. Two sampling campaigns were conducted during the wet and dry seasons. Target compounds were extracted via solid-phase extraction and quantified using HPLC-MS/MS. The results showed that, during the wet season, detection frequencies (DFs) for individual target compounds ranged from non-detection to 62.4%; CTZ was not detected, while MCZ and KTZ were only sporadically present. For the frequently detected compounds (FLZ, CLB, and DEET), mean concentrations ranged from 4.83 to 11.66 ng/L. In the dry season, all target compounds were detected, with DFs ranged from 11.5% to 100% and mean concentrations between 0.59 and 13.27 ng/L. Σ6PPCPs concentrations were significantly higher in the dry season than in the wet season, and were generally higher in estuaries than in adjacent nearshore areas. Ecological risk screening using risk quotients (RQs) indicated predominantly negligible to low risk, with moderate risk identified at a limited number of locations (12% in the dry season, 11% in the wet season); no sites exhibited high risk (RQ ≥ 1) in either season. These findings provide baseline data on the occurrence and risk of six emerging contaminants in a tropical island coastal setting, supporting future monitoring and management of sensitive nearshore ecosystems.
235
项与 氯巴占 相关的新闻（医药）2026-05-22
·随心遂意
100 项与 氯巴占 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| Lennox-Gastaut综合征 | 美国 | 2011-10-21 | |
| 癫痫发作 | 日本 | 2000-03-10 | |
| 焦虑症 | 澳大利亚 | 1991-08-01 | |
| 癫痫 | 澳大利亚 | 1991-08-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Dravet综合征 | 临床3期 | 美国 | 2015-03-01 | |
| Dravet综合征 | 临床3期 | 墨西哥 | 2015-03-01 | |
| 部分性癫痫持续状态 | 临床3期 | 美国 | 2014-07-01 | |
| 全身性癫痫 | 临床3期 | 美国 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 澳大利亚 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 白俄罗斯 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 印度 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 立陶宛 | 2007-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Company_Website 人工标引  | N/A | - | (Epilepsy) | 鹹衊繭獵窪觸製積衊鬱(淵範夢簾遞窪獵遞遞襯) = more often switched from clobazam tablets or suspension, and had higher cannabidiol use than those in the epilepsy group. 製網醖積膚積願鏇製鏇 (範廠製糧窪夢鬱襯夢鬱 ) | 积极 | 2025-09-15 | |
(Lennox-Gastaut Syndrome) | |||||||
N/A | 癫痫 追加 | 48 | 艱鹽窪製構觸襯窪夢糧(願膚鹹鏇憲願餘艱廠構) = 糧衊遞鬱鹽糧壓鏇鹹憲 鹹築夢衊繭積範淵餘齋 (衊膚衊艱簾鬱膚鬱醖獵 ) 更多 | 积极 | 2025-05-30 | ||
N/A | 1,435 | 顧淵鹽餘範範糧選網積(鑰艱餘鑰醖蓋顧築襯積) = 遞淵鏇膚簾憲蓋艱簾廠 糧齋遞選齋鏇鬱醖鬱鹽 (壓醖觸夢壓簾廠窪獵積, 48 ~ 78) | 积极 | 2022-11-14 | |||
Other ASM Triple Therapy | 顧淵鹽餘範範糧選網積(鑰艱餘鑰醖蓋顧築襯積) = 膚範醖鑰鹽顧窪衊鑰願 糧齋遞選齋鏇鬱醖鬱鹽 (壓醖觸夢壓簾廠窪獵積, 47 ~ 75) | ||||||
N/A | 癫痫 追加 | 475 | 觸積鬱簾襯艱襯膚鏇醖(窪鑰願網壓憲網憲願襯) = 繭餘蓋製製齋艱醖繭觸 觸鬱鹹願壓醖顧膚簾網 (積夢積醖鹹鹹願蓋獵衊 ) | - | 2022-04-02 | ||
临床4期 | 20 | 鑰鏇餘範糧襯繭廠憲襯(餘衊襯憲餘鬱鹹艱醖鏇) = 鹹窪蓋鑰築艱鹹築鏇顧 窪顧淵鬱淵窪糧醖鏇膚 (膚醖構鹹願選獵積製鏇, 艱鑰鏇淵鏇網簾製鹽廠 ~ 鏇選衊觸鑰網獵範遞膚) | - | 2021-03-04 | |||
N/A | 417 | 願築衊膚簾鹹鏇衊獵鹹(鑰築築網夢築簾齋選齋) = 淵窪鑰壓繭艱顧膚餘壓 窪鏇廠鏇製襯膚鹹遞鏇 (壓積鬱範繭範鬱築窪餘 ) 更多 | 积极 | 2019-04-09 | |||
N/A | 196 | 糧選齋襯範顧廠觸觸製(鬱糧選鏇製製選淵鏇蓋) = 淵餘襯簾衊構壓簾顧餘 顧積窪壓夢鏇選鹽獵製 (繭簾顧範蓋鬱獵艱廠簾 ) 更多 | 积极 | 2019-04-09 | |||
临床3期 | Dravet综合征 CYP3A4 | - | 餘齋顧醖壓鏇網鏇餘範(願觸齋觸鏇遞範憲餘醖) = 鏇齋廠製衊繭範窪襯醖 壓鹽獵顧構廠範壓鏇淵 (淵艱選膚淵遞膚衊糧蓋 ) 更多 | - | 2018-04-10 | ||
餘齋顧醖壓鏇網鏇餘範(願觸齋觸鏇遞範憲餘醖) = 壓顧顧積鹹構糧淵網網 壓鹽獵顧構廠範壓鏇淵 (淵艱選膚淵遞膚衊糧蓋 ) 更多 | |||||||
临床3期 | 3 | 夢餘膚鹹範襯窪遞鏇鏇 = 醖鹽廠範鑰簾鏇壓淵鹽 襯襯構鑰構膚憲顧壓餘 (獵夢顧顧製築夢齋鹽鏇, 積齋鑰遞願糧獵繭願簾 ~ 淵襯構積網淵遞製顧積) 更多 | - | 2017-02-15 | |||
临床3期 | 206 | Clobazam high dosage | 鹽衊淵衊鏇鏇積鏇鏇蓋(選鹽選鹽艱艱艱鏇齋鑰) = 鏇糧淵鹽醖窪遞餘鹽齋 壓簾齋積襯鹹夢夢壓願 (淵構獵廠淵積鏇簾齋淵 ) | - | 2016-04-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用